NFA
GNMX

Nationwide Fund Advisors’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Nationwide Fund Advisors’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-17,399
Closed -$32K – 3302
2017
Q1 		$32K Hold
17,399
– – ﹤0.01% 3047
2016
Q4 		$90K Sell
17,399
-3,255
-16% -$17.1K ﹤0.01% 2904
2016
Q3 		$115K Buy
20,654
+6,956
+51% +$39.7K ﹤0.01% 2843
2016
Q2 		$76K Hold
13,698
– – ﹤0.01% 3008
2016
Q1 		$60K Hold
13,698
– – ﹤0.01% 2950
2015
Q4 		$82K Buy
13,698
+3,177
+30% +$21.6K ﹤0.01% 2906
2015
Q3 		$82K Hold
10,521
– – ﹤0.01% 2950
2015
Q2 		$64K Buy
+10,521
New +$81.5K ﹤0.01% 3080

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Nationwide Fund Advisors's GNMX Position: Q2 2017 in Review

Nationwide Fund Advisors sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2017, closing a stake of 17,399 shares — an estimated $32K sold.

Nationwide Fund Advisors first reported a position in GNMX in Q2 2015 and held it in 8 quarters. The position peaked at $115K in Q3 2016. 51 funds tracked by Wall St. Rank hold GNMX as of Q2 2017.

  • Nationwide Fund Advisors reported no remaining Aevi Genomic Medicine Inc position as of Q2 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 17,399 Aevi Genomic Medicine Inc shares in Q2 2017, an estimated $32K.
  • Nationwide Fund Advisors first reported a position in Aevi Genomic Medicine Inc in Q2 2015 and held it in 8 quarters.
  • Nationwide Fund Advisors's Aevi Genomic Medicine Inc position peaked at $115K in Q3 2016.
  • 51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2017.

Based on Nationwide Fund Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.